I agree it would, but it’s unclear to me whether they are measuring drug effect on epilepsy.
If they are, it seems to me that Angelman might be a better indication to capture that.
According to the PMS global survey, epilepsy has a prevalence of ~19% in the in the 3-12 age group being assessed in the PMS study.
In comparison, there seems to be a much higher prevalence (60-70%) of epilepsy in Angelman syndrome in the same age group (Angelman Syndrome Foundation).
I note that all four Phase 2 studies exclude participants with an unstable seizure profile.
I agree it would, but it’s unclear to me whether they are...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.38 |
Change
-0.270(1.98%) |
Mkt cap ! $1.710B | |||
| Open | High | Low | Value | Volume |
| $13.68 | $13.68 | $13.11 | $4.283M | 320.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25 | $13.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.40 | 3328 | 3 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |